Literature DB >> 18829695

Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia.

Alessandro Bertolino1, Leonardo Fazio, Grazia Caforio, Giuseppe Blasi, Antonio Rampino, Raffaella Romano, Annabella Di Giorgio, Paolo Taurisano, Audrey Papp, Julia Pinsonneault, Danxin Wang, Marcello Nardini, Teresa Popolizio, Wolfgang Sadee.   

Abstract

Dopamine D2 receptor signalling is strongly implicated in the aetiology of schizophrenia. We have recently characterized the function of three DRD2 SNPs: rs12364283 in the promoter affecting total D2 mRNA expression; rs2283265 and rs1076560, respectively in introns 5 and 6, shifting mRNA splicing to two functionally distinct isoforms, the short form of D2 (D2S) and the long form (D2L). These two isoforms differentially contribute to dopamine signalling in prefrontal cortex and in striatum. We performed a case-control study to determine association of these variants and of their main haplotypes with several schizophrenia-related phenotypes. We demonstrate that the minor allele in the intronic variants is associated with reduced expression of %D2S of total mRNA in post-mortem prefrontal cortex, and with impaired working memory behavioural performance, both in patients and controls. However, the fMRI results show opposite effects in patients compared with controls: enhanced engagement of prefronto-striatal pathways in controls and reduced activity in patients. Moreover, the promoter variant is also associated with working memory activity in prefrontal cortex and striatum of patients, and less robustly with negative symptoms scores. Main haplotypes formed by the three DRD2 variants showed significant associations with these phenotypes consistent with those of the individual SNPs. Our results indicate that the three functional DRD2 variants modulate schizophrenia phenotypes possibly by modifying D2S/D2L ratios in the context of different total D2 density.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829695      PMCID: PMC2640212          DOI: 10.1093/brain/awn248

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  56 in total

Review 1.  Neurotransmitter interactions in schizophrenia--therapeutic implications.

Authors:  A Carlsson; N Waters; M L Carlsson
Journal:  Biol Psychiatry       Date:  1999-11-15       Impact factor: 13.382

2.  Distinct functions of the two isoforms of dopamine D2 receptors.

Authors:  A Usiello; J H Baik; F Rougé-Pont; R Picetti; A Dierich; M LeMeur; P V Piazza; E Borrelli
Journal:  Nature       Date:  2000-11-09       Impact factor: 49.962

3.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Authors:  A Abi-Dargham; J Rodenhiser; D Printz; Y Zea-Ponce; R Gil; L S Kegeles; R Weiss; T B Cooper; J J Mann; R L Van Heertum; J M Gorman; M Laruelle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

4.  Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI.

Authors:  D Y Kimberg; G K Aguirre; J Lease; M D'Esposito
Journal:  Hum Brain Mapp       Date:  2001-04       Impact factor: 5.038

5.  Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs.

Authors:  M S Lidow; J D Elsworth; P S Goldman-Rakic
Journal:  J Pharmacol Exp Ther       Date:  1997-04       Impact factor: 4.030

6.  Modulation of memory fields by dopamine D1 receptors in prefrontal cortex.

Authors:  G V Williams; P S Goldman-Rakic
Journal:  Nature       Date:  1995-08-17       Impact factor: 49.962

7.  Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited.

Authors:  J H Callicott; A Bertolino; V S Mattay; F J Langheim; J Duyn; R Coppola; T E Goldberg; D R Weinberger
Journal:  Cereb Cortex       Date:  2000-11       Impact factor: 5.357

8.  Antipsychotic regulation of dopamine D1, D2 and D3 receptor mRNA.

Authors:  U D'Souza; P McGuffin; P R Buckland
Journal:  Neuropharmacology       Date:  1997 Nov-Dec       Impact factor: 5.250

9.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

Authors:  Y Okubo; T Suhara; K Suzuki; K Kobayashi; O Inoue; O Terasaki; Y Someya; T Sassa; Y Sudo; E Matsushima; M Iyo; Y Tateno; M Toru
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

10.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

Authors:  M Laruelle; A Abi-Dargham; C H van Dyck; R Gil; C D D'Souza; J Erdos; E McCance; W Rosenblatt; C Fingado; S S Zoghbi; R M Baldwin; J P Seibyl; J H Krystal; D S Charney; R B Innis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

View more
  66 in total

1.  What is a functional genetic polymorphism? Defining classes of functionality.

Authors:  Paul R Albert
Journal:  J Psychiatry Neurosci       Date:  2011-11       Impact factor: 6.186

Review 2.  mRNA transcript diversity creates new opportunities for pharmacological intervention.

Authors:  Elizabeth S Barrie; Ryan M Smith; Jonathan C Sanford; Wolfgang Sadee
Journal:  Mol Pharmacol       Date:  2012-02-07       Impact factor: 4.436

Review 3.  Genetic neuropathology of schizophrenia: new approaches to an old question and new uses for postmortem human brains.

Authors:  Joel E Kleinman; Amanda J Law; Barbara K Lipska; Thomas M Hyde; Justin K Ellis; Paul J Harrison; Daniel R Weinberger
Journal:  Biol Psychiatry       Date:  2011-01-15       Impact factor: 13.382

4.  DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.

Authors:  Giuseppe Blasi; Francesco Napolitano; Gianluca Ursini; Paolo Taurisano; Raffaella Romano; Grazia Caforio; Leonardo Fazio; Barbara Gelao; Annabella Di Giorgio; Luisa Iacovelli; Lorenzo Sinibaldi; Teresa Popolizio; Alessandro Usiello; Alessandro Bertolino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

5.  Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.

Authors:  Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder
Journal:  Psychopharmacology (Berl)       Date:  2011-07-13       Impact factor: 4.530

6.  Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

Authors:  Colm M P O'Tuathaigh; Brian P Kirby; Paula M Moran; John L Waddington
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

7.  Genetically determined interaction between the dopamine transporter and the D2 receptor on prefronto-striatal activity and volume in humans.

Authors:  Alessandro Bertolino; Leonardo Fazio; Annabella Di Giorgio; Giuseppe Blasi; Raffaella Romano; Paolo Taurisano; Grazia Caforio; Lorenzo Sinibaldi; Gianluca Ursini; Teresa Popolizio; Emanuele Tirotta; Audrey Papp; Bruno Dallapiccola; Emiliana Borrelli; Wolfgang Sadee
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

8.  Effects of neuregulin 3 genotype on human prefrontal cortex physiology.

Authors:  Heike Tost; Joseph H Callicott; Roberta Rasetti; Radhakrishna Vakkalanka; Venkata S Mattay; Daniel R Weinberger; Amanda J Law
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

9.  Dopamine D2L Receptor Deficiency Causes Stress Vulnerability through 5-HT1A Receptor Dysfunction in Serotonergic Neurons.

Authors:  Norifumi Shioda; Yoshiki Imai; Yasushi Yabuki; Wataru Sugimoto; Kouya Yamaguchi; Yanyan Wang; Takatoshi Hikida; Toshikuni Sasaoka; Michihiro Mieda; Kohji Fukunaga
Journal:  J Neurosci       Date:  2019-08-01       Impact factor: 6.167

10.  Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants.

Authors:  Ajna Hamidovic; Andrea Dlugos; Andrew Skol; Abraham A Palmer; Harriet de Wit
Journal:  Exp Clin Psychopharmacol       Date:  2009-12       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.